AP-4-139B 是一种可穿过血脑屏障的 HSP70 抑制剂,对 hHSP70 的 IC50 为 180 nM,可直接结合 HSP70 并抑制其 ATP 酶活性,通过增加 Beclin-1 磷酸化促进自噬 (Autophagy),在结直肠癌和胰腺导管腺癌临床前模型中具有抗肿瘤作用。
产品编号: MS-Q74891 纯度: 98.87% CAS No.: 2716909-84-9 分子式: C34H33BrN3PS 分子量: 626.59
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价

产品描述

AP-4-139B 是一种可穿过血脑屏障的 HSP70 抑制剂,对 hHSP70 的 IC50 为 180 nM,可直接结合 HSP70 并抑制其 ATP 酶活性,通过增加 Beclin-1 磷酸化促进自噬 (Autophagy),在结直肠癌和胰腺导管腺癌临床前模型中具有抗肿瘤作用。

生物实验数据

生物活性 AP-4-139B is a blood-brain barrier-penetrant HSP70 inhibitor with an IC50 of 180 nM against hHSP70 that directly binds HSP70 and inhibits its ATPase activity, promotes autophagy by increasing Beclin-1 phosphorylation, and exhibits antitumor effects in preclinical models of colorectal cancer and pancreatic ductal adenocarcinoma.
IC50 & Target HSP70:180 nM
体外研究
(In Vitro)

AP-4-139B 可强效抑制纯化的 hHSP70 ATP 酶活性,IC50 为 180 nM。
AP-4-139B (500 nM; 24 h) 会损伤 1205Lu 黑色素瘤细胞和 HT-29 结直肠癌细胞的线粒体功能 (基础 OCR 和 ATP 生成降低),而对 IMR90 人成纤维细胞或 CCD 841 CoN 正常结肠上皮细胞无显著影响。
AP-4-139B (48 h) 对结直肠癌 (CRC) 细胞系具有强细胞毒性 (IC50 1.5-3 μM)。
AP-4-139B (1-5 μM; 24 h) 可在 TCC-Pan2、PK-8、MIA PaCa-2 和 PANC-1 胰腺导管腺癌 (PDAC) 细胞中诱导自噬,Beclin-1 磷酸化水平升高及 LC3B 脂化可作为该作用的佐证。
AP-4-139B (0.19-15 μM; 72 h) 可与自噬抑制剂氯喹协同作用,降低 TCC-Pan2、PK-8、MIA PaCa-2 和 PANC-1 胰腺导管腺癌 (PDAC) 细胞的活力。

Western Blot Analysis

Cell Line: Hs766T, PANC-1, MIA PaCa-2
Concentration: 5 μM (Hs766T, PANC-1); 2.5 μM (MIA PaCa-2)
Incubation Time: 24-72 h (Hs766T, PANC-1); 48-72 h (MIA PaCa-2)
Result: Caused a time-dependent decrease in DRP1 phosphorylation at serine 616 in Hs766T cells, with significant reductions observed at 24, 48, and 72 h compared to untreated cells.
Caused a time-dependent decrease in DRP1 phosphorylation at serine 616 in PANC-1 cells, with significant reductions observed at 24, 48, and 72 h compared to untreated cells.
Caused a time-dependent decrease in DRP1 phosphorylation at serine 616 in MIA PaCa-2 cells, with significant reductions observed at 48 and 72 h compared to untreated cells.

Western Blot Analysis

Cell Line: TCC-Pan2, PK-8, MIA PaCa-2, PANC-1
Concentration: 1-5 μM
Incubation Time: 24 h
Result: Caused a dose-dependent increase in phospho-Beclin-1 (S93) levels and LC3B-II levels in TCC-Pan2 cells compared to untreated cells.
Caused a dose-dependent increase in phospho-Beclin-1 (S93) levels and LC3B-II levels in PK-8 cells compared to untreated cells.
Caused a dose-dependent increase in phospho-Beclin-1 (S93) levels and LC3B-II levels in MIA PaCa-2 cells compared to untreated cells.
Caused a dose-dependent increase in phospho-Beclin-1 (S93) levels and LC3B-II levels in PANC-1 cells compared to untreated cells.
体内研究
(In Vivo)

AP-4-139B (12.5 mg/kg;每周 3 次) 可显著抑制 HT-29 结直肠癌异种移植物的进展。
AP-4-139B (10 mg/kg,每 48 小时一次) 可显著抑制 MC38 结直肠癌异种移植瘤的进展,并促进免疫细胞向肿瘤组织募集,且无全身毒性。
AP-4-139B (10 mg/kg;腹腔注射;隔日 1 次) 可在体内显著抑制 PK-8 PDAC 异种移植瘤的生长。

Animal Model: NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) (male, 6-8 week old, subcutaneous injection of 2.5 x 106 HT-29 cells)
Dosage: 12.5 mg/kg
Administration: three times per week
Result: Significantly reduced HT-29 tumor xenograft progression relative to control (p<0.001).
Reduced Ki-67-positive proliferative cells in tumor tissue relative to control.
Reduced staining for HSP70 client proteins NDUFA6 and mutant p53 in tumor tissue relative to control.
Increased staining for cleaved lamin A (apoptosis marker) in tumor tissue relative to control.
Showed no signs of toxicity (weight loss, abnormal liver/colon architecture).
Animal Model: C57Bl/6J (male, 6-8 week old, subcutaneous injection of 1 x 106 MC38 cells)
Dosage: 10 mg/kg
Administration: every 48 hours
Result: Significantly reduced MC38 tumor xenograft progression relative to control (p<0.001).
Increased infiltration of CD8+ T cells, Granzyme B-positive activated T cells, conventional CD4+ T cells, regulatory T cells (Tregs), and dendritic cells in tumor tissue relative to control.
Showed no changes in CD8+ T cells, Granzyme B-positive activated T cells, conventional CD4+ T cells, regulatory T cells (Tregs), and dendritic cell populations in mouse spleens relative to control.
Showed no signs of toxicity (weight loss).
Animal Model: NSG mice (subcutaneous injection of PK-8 cells)
Dosage: 10 mg/kg
Administration: i.p.; every other day
Result: Significantly reduced tumor volume and tumor weight at endpoint compared to vehicle controls.
Caused no significant weight loss.
性状 固体
颜色 White to off-white

化学信息

分子量 626.59
分子式 C34H33BrN3PS
CAS No. 2716909-84-9

储存&溶解度

储存方式

-20°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (159.59 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.5959 mL7.9797 mL15.9594 mL39.8985 mL
5 mM0.3192 mL1.5959 mL3.1919 mL7.9797 mL
10 mM0.1596 mL0.7980 mL1.5959 mL3.9898 mL
15 mM0.1064 mL0.5320 mL1.0640 mL2.6599 mL
20 mM0.0798 mL0.3990 mL0.7980 mL1.9949 mL
25 mM0.0638 mL0.3192 mL0.6384 mL1.5959 mL
30 mM0.0532 mL0.2660 mL0.5320 mL1.3299 mL
40 mM0.0399 mL0.1995 mL0.3990 mL0.9975 mL
50 mM0.0319 mL0.1596 mL0.3192 mL0.7980 mL
60 mM0.0266 mL0.1330 mL0.2660 mL0.6650 mL
80 mM0.0199 mL0.0997 mL0.1995 mL0.4987 mL
100 mM0.0160 mL0.0798 mL0.1596 mL0.3990 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础